acr325
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT01023282)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine D2 receptorMODULATOR
DRD2 modulator
Dopidine (dopaminergic stabilizer)
Chemistry & pharmacology
Loading structure…
SMILES
CCN1CCC(c2cccc(S(C)(=O)=O)c2F)CC1- Mol. weight
- 285.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545010 ↗
Also known as
- acr325
- acr325
- acr-325
- acr-325
- ordopidine
- ordopidine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01023282 | Phase 1 | Nov 1, 2009 | NeuroSearch A/S |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NeuroSearch A/S | For profit | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1